Literature DB >> 8794251

The UNOS scientific renal transplant registry. United Network for Organ Sharing.

J M Cecka1, P I Terasaki.   

Abstract

Overall one-, 5-, and projected 10-year graft survival rates were 81%, 58% and 39%, respectively for 51,442 cadaveric kidney transplants performed at 251 U.S. transplant centers from October 1987-December 1994. The comparable results for recipients of living donor kidneys were significantly higher, 91%, 75%, and 60% (p<0.001). One-year first cadaver graft survival rates improved from 77% for transplants performed in 1987-1988 to 84% for transplants performed in 1991-1992 (p<0.001). Recipients of second cadaveric transplants in 1987-1988 had a 69% one-year graft survival rate compared with 81% for those transplanted after 1990 (p<0.001). Graft survival rates have been stable since 1991. The percentage of broadly sensitized first transplant recipients decreased from 13% before 1991 to 7% after, and the one-year graft survival rates increased by 4-6% for both sensitized and nonsensitized recipients between the 2 periods (p<0.001). Among retransplanted patients, the percent of broadly sensitized recipients fell from 40-33% over the same periods (p<0.01). One-year graft survival rates increased by 7-8% for sensitized and nonsensitized patients (p<0.001). One-year graft survival rates improved from 74-83% for Blacks (p<0.001) and from 78-85% for non-Blacks (p<0.001) transplanted for the first time when comparing transplants performed in 1987-88 with those performed in 1993-94. The cause of donor death had a significant effect on graft survival. The 5-year graft survival rate was 61% for 28,923 recipients of trauma donor kidneys compared with 54% for 16,956 transplants from CVA donors (p<0.001). Kidneys from CVA donors increased from 28% of all cadaveric kidneys in 1988 to 38% in 1994. The donor's age was a more important determinant of long-term survival, however, and correlated strongly with the cause of donor death. Only 16% of CVA donors were reportedly age 30 or less, compared with 75% of trauma donors. First cadaver graft survival decreased by approximately 2% for each 12 hours of cold ischemia time. Although there was a significant increase in the incidence of delayed graft function from 19% when the CIT was less than 12 hours to 35% when the CIT was more than 36 hours, there was no significant long-term effect of cold ischemia time. The recent change in UNOS policy to share zero-HLA mismatched kidneys resulted in a 2-fold increase (from 8%-16%) in the number of HLA-matched transplants performed during the first 6 months following the change. The percentage of Blacks who have received matched kidneys following this change has increased from less than 2% to more than 5%, a 3-fold increase. The 163 Blacks who received an HLA-matched kidney prior to 1995 had a 65% 4-year graft survival rate compared with 53% for mismatched Blacks (p<0.001). The incidence of early rejections was also reduced by 25% among matched recipients and the graft half-life was 8 years compared with 5 years for mismatched Blacks. About 25% of HLA-matched kidneys were transplanted to ABO compatible but not identical recipients. Although the effect of the policy allowing compatible transplants did not result in a large number of type O kidneys transplanted to non-O recipients when only 8% of kidneys were shared, the recent change in allocation policy may be detrimental to type O waiting patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8794251

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  8 in total

1.  Gastrointestinal complications in renal transplant recipients detected by endoscopic biopsies in a developing country.

Authors:  Muhammed Ishaque; Rahma Rashid; Muhammed Mubarak
Journal:  Indian J Gastroenterol       Date:  2015-03-12

2.  National recommendations for donation after cardiocirculatory death in Canada: Donation after cardiocirculatory death in Canada.

Authors:  Sam D Shemie; Andrew J Baker; Greg Knoll; William Wall; Graeme Rocker; Daniel Howes; Janet Davidson; Joe Pagliarello; Jane Chambers-Evans; Sandra Cockfield; Catherine Farrell; Walter Glannon; William Gourlay; David Grant; Stéphan Langevin; Brian Wheelock; Kimberly Young; John Dossetor
Journal:  CMAJ       Date:  2006-10-10       Impact factor: 8.262

3.  Vascular access for chronic hemodialysis in children: arteriovenous fistula or central venous catheter?

Authors:  Aicha Merouani; Michel Lallier; Julie Paquet; Johanne Gagnon; Anne Laure Lapeyraque
Journal:  Pediatr Nephrol       Date:  2014-08-08       Impact factor: 3.714

4.  Renal transplantation using non-heart-beating donors: a potential solution to the organ donor shortage in Canada.

Authors:  Julie D Lacroix; John E Mahoney; Greg A Knoll
Journal:  Can J Surg       Date:  2004-02       Impact factor: 2.089

5.  Anti-Apoptotic Effects of 3,3',5-Triiodo-L-Thyronine in the Liver of Brain-Dead Rats.

Authors:  Rolando A Rebolledo; Anne C Van Erp; Petra J Ottens; Janneke Wiersema-Buist; Henri G D Leuvenink; Pamela Romanque
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

6.  The Effect of Osmotherapy and Tight Control of Acidosis on Early Graft Function among Deceased-Donor Kidney Transplant Recipients: A Randomized Controlled Trial.

Authors:  F Etezadi; A H Najafi Abrandabadi; J Motaharinia; M Mojtahedzadeh; P Pourfakhr; M R Khajavi; S Gooran; R Shariat Moharari; S Dehghani
Journal:  Int J Organ Transplant Med       Date:  2017-02-01

Review 7.  Laparoscopic live donor nephrectomy: a step forward in kidney transplantation?

Authors:  George Skrekas; Vassilios E Papalois; Michail Mitsis; Nadey S Hakim
Journal:  JSLS       Date:  2003 Jul-Sep       Impact factor: 2.172

8.  Predictive Values of Urinary Interleukin 18 and Neutrophil Gelatinase-Associated Lipocalin for Delayed Graft Function Diagnosis in Kidney Transplantation.

Authors:  Mojtaba Mojtahedzadeh; Farhad Etezadi; Javad Motaharinia; Amir Hossein Najafi Abrandabadi; Abdorasul Mehrsai; Shadi Ziaie; Soheil Saadat
Journal:  Iran J Pathol       Date:  2016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.